Express News | HC Wainwright & Co. Reiterates Neutral on Panbela Therapeutics
H.C. Wainwright Maintains Panbela Therapeutics(PBLA.US) With Hold Rating
Express News | Panbela Therapeutics Inc: Enrollment Positions Co for Enrollment Completion by Q1 2025
Express News | Panbela Therapeutics Inc: Interim Survival Analysis Still Expected Early 2025
Express News | Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 Aspire Clinical Trial Dsmb Recommended Continuation With No Trial Modification
Panbela Therapeutics at Risk: Penny Stock Classification May Weaken Legal Safeguards and Hurt Valuation
Express News | Panbela Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy
Panbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
Panbela Therapeutics | 10-Q: Quarterly report
Earnings Call Summary | Panbela Therapeutics(PBLA.US) Q1 2024 Earnings Conference
Express News | Panbela Provides Business Update and Reports Q1 2024 Financial Results
Panbela Therapeutics Announces Delay of Expected Data From Pancreatic Cancer Treatment Trial
Panbela Therapeutics Updates ASPIRE Trial Timeline
Express News | Panbela Therapeutics Inc: Interim Data Analysis for Aspire Trial Pushed to Q1 2025
Panbela Applies to List on CBOE
Panbela Therapeutics, Recently Delisted From Nasdaq and Now on OTCQB, to Seek CBOE Stock Listing
Panbela Therapeutics Files for Stock and Warrant Offering
Express News | Panbela Announces Poster Presentation at American Association for Cancer Research:
Panbela Therapeutics Shifts From Nasdaq to OTCQB Market
Panbela Announces Transfer to OTCQB Market
No Data